PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons
E-Collection

Related Articles
Design and Evolution: Molecular Sleuthing Reveals Drug Selectivity
June 2015
Families in Gene Neighborhoods
June 2015
Ryanodine Receptor
April 2015
CCR5 and HIV Infection
January 2015
Drug Targets: Bile Acids in Motion
September 2014
Drug Targets: S1R's Ligands and Partners
September 2014
P2Y Receptors and Blood Clotting
September 2014
Bacterial CDI Toxins
June 2014
Glucagon Receptor
April 2014
Viroporins
March 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Design and Discovery: Virtual Drug Screening
January 2014
Cancer Networks: IFI16-mediated p53 Activation
November 2013
G Proteins and Cancer
November 2013
Drug Discovery: Antidepressant Potential of 6-NQ SERT Inhibitors
October 2013
Drug Discovery: Finding Druggable Targets
October 2013
Drug Discovery: Identifying Dynamic Networks by CONTACT
October 2013
Drug Discovery: Modeling NET Interactions
October 2013
Membrane Proteome: GPCR Substrate Recognition and Functional Selectivity
August 2013
Infectious Diseases: Determining the Essential Structome
May 2013
NDM-1 and Antibiotics
May 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Cytochrome Oxidase
November 2012
Membrane Proteome: The ABCs of Transport
November 2012
Bacterial Phosphotransferase System
October 2012
Regulatory insights
September 2012
Solute Channels
September 2012
Pocket changes
July 2012
Receptor bias
July 2012
Anthrax Stealth Siderophores
June 2012
G Protein-Coupled Receptors
May 2012
Substrate specificity sleuths
April 2012
Reading out regioselectivity
December 2011
Superbugs and Antibiotic Resistance
December 2011
Terminal activation
December 2011
A change to resistance
November 2011
Docking and rolling
October 2011
Breaking down the defenses
September 2011
A2A Adenosine Receptor
May 2011
Cell wall recycler
May 2011
Subtly different
March 2011
CXCR4
January 2011
Subtle shifts
January 2011
ABA receptor diversity
November 2010
COX inhibition: Naproxen by proxy
November 2010
Zinc Transporter ZntB
July 2010
Peptidoglycan binding: Calcium-free killing
June 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Antibiotics and Ribosome Function
March 2010
Safer Alzheimer's drugs?
March 2010
Anthrax evasion tactics
September 2009
GPCR subunits: Separate but not equal
September 2009
Antibiotic target
August 2009
Salicylic Acid Binding Protein 2
August 2009
Lysostaphin
July 2009
Tackling influenza
June 2009
Bacterial Leucine Transporter, LeuT
May 2009
Anthrax stealth molecule
March 2009
Drug targets to aim for
February 2009
High-energy storage system
February 2009
Transporter mechanism in sight
February 2009
Scavenger Decapping Enzyme DcpS
November 2008
Blocking AmtB
September 2008

Research Themes Drug discovery

Drug Targets: S1R's Ligands and Partners

SBKB [doi:10.1038/sbkb.2014.219]
Featured Article - September 2014
Short description: Stabilization of oligomers by small-molecule ligands suggests a mechanism for regulating a membrane protein chaperone.

Proposed model showing interconversions of S1R between the monomer form and ligand-stabilized oligomeric forms. Figure courtesy of Brian Fox.

Mammalian protein sigma 1 receptor (S1R) is a membrane-bound protein that functions as a molecular chaperone for a variety of receptors and voltage-gated ion channels. S1R is implicated in drug addiction and neurodegenerative diseases, and is regulated by a broad range of endogenous ligands such as sphingosine and steroids, as well as synthetic and naturally occurring small-molecule molecules, including cocaine and haloperidol. Previous studies suggested that S1R contains two transmembrane helices and a cytoplasmic C-terminal domain; the latter is involved in chaperone activity, whereas the ligand-binding region is formed by a short hydrophobic portion in the C-terminal domain, a portion of TM2 and possibly a portion of TM1.

To understand the mechanism of S1R activation, Fox and colleagues (PSI TMPC) examined the possibility that S1R oligomerizes under physiological conditions, as suggested by previous results from the Ruoho laboratory. The authors purified protein dodecyl maltoside detergent micelles of guinea pig S1R fused to maltose-binding protein (MBP). S1R eluted as at least two species on analytical size-exclusion chromatography (SEC), both before and after MBP was cleaved away. SEC and light-scattering analyses indicated that the low molecular weight (MW) peak corresponded to a monomer, the high MW peak to oligomeric states of 6–8, and the intermediate MW peak to a tetramer (only seen for MBP-fused S1R). These oligomerization states were supported by SDS-PAGE analysis following treatment with a crosslinker agent. Dissociation of high-MW oligomers into monomers increased with temperature, and incubation with a variety of known S1R ligands reduced heat-induced dissociation. Assaying isolated monomers and oligomers revealed that only the oligomers had ligand-binding activity.

Based on these results, the authors propose that ligand binding may regulate chaperone activity by sequestering S1R into oligomeric states unable to bind client proteins. To determine whether the GxxxG motif in TM2 promotes helix-helix association as seen in other transmembrane proteins, glycine residues 87, 88 and 91 were mutated to isoleucine or leucine. These point mutations drastically reduced the yield of purified S1R protein, markedly shifting the distribution from oligomeric to monomeric forms, and reduced [3H]-(+)-pentazocine binding at the single concentration tested. The latter results are consistent with previous findings by Ruoho and colleagues, implicating residues 91–109 on TM2 in ligand binding.

This work points to possible mechanisms of molecular regulation of interacting protein partners by S1R in the presence of small-molecule ligands. Further analysis is needed to determine how ligand binding promotes S1R oligomerization and the impact on chaperone activity.

Anita M. Engh

References

  1. K. Gromek et al. The oligomeric states of the purified sigma 1 receptor are stabilized by ligands.
    J Biol Chem. 289, 20333-20344 (2014). doi:10.1074/jbc.M113.537993

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health